[Skip to Content]
[Skip to Content Landing]
Special Contribution
September 7, 1964

Multiple Myeloma: II. Analysis of Cyclophosphamide Therapy in 165 Patients

Author Affiliations

Ann Arbor, Mich; New York; Iowa City, Iowa; Chicago; Cincinnati; Columbus, Ohio

Dr. Korst is chairman of this study. Dr. Louis is chairman of the Midwest Cooperative Chemotherapy Group. For the members of the group see page 762.

JAMA. 1964;189(10):758-762. doi:10.1001/jama.1964.03070100052010

A COOPERATIVE STUDY of a treatment of myeloma by 21 institutions has been in progress for four years.1 A uniform protocol, criteria, and data flow sheets have been followed and evaluated by the committee. Comparison survival data with previous forms of treatment was obtained in an ancillary myeloma study by the same cooperative group in the same institutions.2 Cyclophosphamide (Cytoxan) was selected as an alkylating agent suitable for use in a low oral dose, longrange program. These results are based on a study of 165 patients who received the drug for at least 60 days (an "adequate trial"). Twenty percent (42) of the patients who started the study did not reach adequate trial status because of death (17), complications (8), or loss to follow-up (17).

Materials and Methods  Participating investigators placed on study as many patients as possible from their respective institutions. The diagnosis of multiple myeloma was